09:26 AM EDT, 06/17/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) on Tuesday said the first person with multiple sclerosis (MS) has been scanned in a joint study with Massachusetts General Hospital to test a new positron emission tomography (PET) imaging technique.

The study is also evaluating a particular PET "tracer" which could act as a biomarker to monitor changes in demyelination which may occur in response to treatment, a statement said. Quantum BioPharma's ( QNTM ) lead compound, Lucid-MS, has been shown to prevent and reverse myelin degradation, the underlying mechanism of MS.

"We are excited that the study has started and that we are learning more about the potential of this novel PET biomarker to directly visualize and measure demyelinated axons in the central nervous system," said Dr. Andrzej Chruscinski, vice-president, scientific and clinical affairs.